Earnings ·
Vaxcyte, Inc. reported financial results for the quarter ended June 30, 2026, posting a net loss of $284.3 million…
PCVXVaxcyte, Inc.
Vaxcyte, Inc. reported financial results for the quarter ended June 30, 2026, posting a net loss of $284.3 million compared to $166.6 million in the prior year period. Research and development expenses increased to $267.9 million from $194.2 million due to higher manufacturing costs for PCV programs and clinical trial expenses. The company held approximately $2.5 billion in cash, cash equivalents, and investments as of June 30, 2026. Clinically, the VAX-31 adult Phase 3 OPUS trials are fully enrolled with 6,191 participants dosed; topline data from the pivotal OPUS-1 trial is expected in Q4 2026, while OPUS-2 and OPUS-3 results are anticipated in H1 2027. The company also initiated a Phase 1 study for VAX-A1 against Group A Streptococcus. Additionally, Dr. Moncef Slaoui and Dr. John Markels were appointed to the Board of Directors, replacing retiring members Jacks Lee and Dr. Heath Lukatch. Vaxcyte is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect against bacterial diseases.